Advanced Search
Contact | Corporate | Help

News Archive of FiercePharma

ArticleAdded
FDA panel draws blood in Xarelto's bid for new use05-24-12
Sanofi eyes Chinese cancer market with early drug trial05-24-12
Another German drugmaker, Riemser Arzneimittel, on the block 05-24-12
New Teva chief slashes sales forecast by $1B05-24-12
EU antitrust officials probe parallel trade 05-24-12
Securities watchdogs reportedly probe Shanghai Pharma deals05-24-12
Study: Docs barring pharma reps has unexpected side effects05-23-12
Pfizer taps new emerging markets chief as Simmons exits05-23-12
NICE nod for Xarelto as FDA panel mulls new use05-23-12
Pfizer adds healthy-eating app to Lipitor marketing arsenal05-23-12
Merck CEO assures shareholders there is life after death of Singulair patent 05-23-12
New use for Humira delayed as Abbott preps for spinoff05-23-12
Docs barring pharma reps has unexpected side effects: study05-23-12
States plea to AG for help getting execution drugs05-22-12
More evidence supports fracture risk with long-term bisphosphonate use05-22-12
Fired Pfizer rep sues, claiming pregnancy-related discrimination05-22-12
Pharma dealmakers, the price is right for Sweden's Meda05-22-12
Private equity owner seeks $510M-plus deal for Germany's Aenova05-22-12
Bayer's Nexavar falters in another lung cancer trial05-22-12
UPDATED: Pfizer recalled 653,000 bottles of smelly Advil05-21-12
CDC delivers gift to hep C drugmakers05-21-12
FDA in line for new foreign-inspection powers05-21-12
GSK inks deal to co-promote Auxilium testosterone gel05-21-12
Pfizer recalled 653,000 bottles of smelly Advil05-21-12
FDA review backs Xarelto for big new use in ACS patients05-21-12
How does pharma's CEO pay rank?05-21-12
Even some domestic firms rail at India's price control plan05-18-12
Reuters: Drugmakers crafting emergency plan for Greece05-18-12
Johnson & Johnson recalls a lot of Imodium05-18-12
Drugmakers rail against India's move toward price controls05-18-12
Warner Chilcott sues Watson to stop generic contraceptive 05-18-12
Employers eye costs of specialty drugs05-18-12
Generic floodgates open for Plavix in U.S.05-17-12
J&J's Zytiga may be useful in early prostate cancer, too05-17-12
SEC probes Dendreon amid shareholder lawsuits05-17-12
Study links Z-Pak with risk of sudden death05-17-12
HGS puts 'poison pill' in its arsenal against GSK05-17-12
Another one bites the dust: Plavix falls off patent today05-17-12
Pfizer's targeted drug knocks out child cancers in small study05-17-12
Ex-BMS exec finishes book, and sentence, in conviction05-16-12
U.K. report says NICE drags its feet on drug approvals05-16-12
ASCO data to shine new light on Pfizer, Roche, J&J drugs 05-16-12
NIH taps Genentech drug for pioneering Alzheimer's study 05-16-12
Pennsylvania still trying get a slice of J&J Risperdal payouts05-16-12
New discount persuades NICE to bless J&J's Zytiga05-16-12
Top 10 Best-selling Cancer Drugs in 201105-16-12
Merck KGaA reveals $385M in cuts as Geneva protests continue05-15-12
Private equity firms snap up 50% of Rottapharm05-15-12
U.K. officials demand action on worsening drug shortages05-15-12
Drugmakers don't have apps for that--yet05-15-12
Big-name pharmas peer at Amylin's books to prep for bids05-15-12
Payers likely to throw up hurdles to Pfizer's new RA drug 05-15-12
Clinical trials to size up antipsychotics like Seroquel for PTSD05-14-12
Eisai broadens marketing deal for Arena's weight-loss drug05-14-12
Sales-needy Takeda springs for emerging markets growth05-14-12
Servier, founder face trial on Mediator charges 05-14-12
Shantha gets go-ahead for operational revamp05-14-12
Serono workers threaten strike against HQ shutdown05-14-12
India's drug regulator says it will clean up its act05-11-12
Dr. Reddy's profits up but pales with Ranbaxy05-11-12
Rebates cut $40B off drugmakers' returns05-11-12
FDA review questions long-term use of bone-building drugs05-11-12
Merck notches a win in Vioxx litigation 05-11-12
FDA advisory panel backs Truvada for HIV prevention05-11-12
A strike against sales-rep OT as Lilly, Abbott win appeal05-10-12
J&J opens up Doxil rationing on 'limited' new supply05-10-12
Glaxo can nail HGS buy with slightly bigger bid, analysts say05-10-12
Roche's Tarceva wins NICE nod for first-line use05-10-12
Indian panel accuses Big Pharma of colluding with regulators05-10-12
With generics horde advancing, Pfizer gives up Lipitor push05-10-12
Lipitor copy powers a surge in Ranbaxy sales, profits05-09-12
DSM panel holds firm on new autism diagnosis, ditches 2 other revisions05-09-12
Glaxo goes hostile on HGS with $2.6B bid05-09-12
Advisory panels take up Gilead's Truvada, then Quad05-09-12
Senate probes ties among narcoticsmakers, pain organizations05-09-12
FDA panel nixes Regeneron's Arcalyst for gout05-09-12
Activist investor presses Par Pharma to sell itself05-08-12
Docs riled by FDA's proposal to open up drug access05-08-12
Sanofi plant starts shutdown with 112 layoffs05-08-12
Europe may be austere, but it's also hiring in pharma05-08-12
Novartis may weigh Lucentis price cut in U.K.05-08-12
Abbott to pay $1.6B to wrap up Depakote marketing probe05-07-12
As Lipitor gets more rivals, Lyrica studies fall short05-07-12
Roche gives up on anticipated 'good cholesterol' drug05-07-12
Bayer slams Indian government, Cipla on Nexavar copies05-07-12
Truvada up for FDA debate as HIV preventive05-07-12
Congress drags Big Pharma into Obamacare negotiation probe05-07-12
Pharma continues parachute-building for patent cliff05-07-12
India's Cipla puts fire-sale prices on cancer drugs05-04-12
Warner Chilcott lowers outlook 05-04-12
Drug shortages have fallen dramatically, FDA says05-04-12
Pfizer, Lilly, AstraZeneca giving NIH abandoned drugs05-04-12
Feds nab suspects in $70M Lilly heist05-04-12
GSK's Witty has no interest in buying AstraZeneca05-04-12
Roche moves forward with injectable Actemra 05-03-12
German gatekeepers nix GSK's lupus drug Benlysta05-03-12
Novartis now top dog in skin drugs with $1.5B Fougera buy05-03-12
Study eyes mechanisms to blame for Vioxx risks 05-03-12
Pharma's biotech buyouts stymied by price05-03-12
Analysts size up Warner Chilcott's merits for sale05-03-12
Novartis digs into safety data in Avastin-vs.-Lucentis study05-02-12
Pfizer settles Celebrex royalty suit for $450M05-02-12
Pfizer aims at Genzyme with Gaucher drug approval05-02-12
Hedge fund claims Savient's bankrupt after failed Krystexxa launch05-02-12
Men flock to testosterone meds from Abbott, Lilly05-02-12
IOM takes FDA to task on post-marketing safety05-02-12
France replaces drug regulator with new agency05-01-12
Many U.S. companies not top drugsellers in U.S. 05-01-12
Teva exec: Euro price cuts may trigger generics shortages05-01-12
Avastin, Lucentis equally effective at improving vision, big study finds05-01-12
Abbott tries to throw up roadblock to Humira biosim05-01-12
Lipitor swoons, taking Pfizer's pharma sales down 25%05-01-12
Who's missing from the CEO pay list? Short answer: Europeans05-01-12
Sanofi has terrific first quarter, but next 3 will be tough04-30-12
Pharma rides a wave of targeted M&A deals04-30-12
Merck wins patent fight on Zetia, Vytorin; Fitch warns of 'pure pharma' risks;04-30-12
Stendra approval in hand, Vivus looks like a target04-30-12
Here's a hit list for AstraZeneca's CEO search committee04-30-12
Times: AstraZeneca CEO up for $65M goodbye04-30-12
Interested shoppers prompt Warner to weigh sale options04-30-12
Pfizer, Roche, GSK said to be knocking heads with generics on EU drug tracking 04-27-12
Boosted by Januvia, Merck bests expectations by a penny04-27-12
Jazz Pharmaceuticals announces another deal04-26-12
Bristol-Myers hits estimates for the quarter but still faces tough going04-27-12
Amgen gets a no from the FDA on extended use of Xgeva04-27-12
Bristol-Myers Squibb confirms it's a target of bribery probe04-27-12
Gorsky starts the marathon task of rehabbing J&J04-26-12
Icahn calls a truce with Amylin after CEO chat04-26-12
BMS delivers sales, profit growth in Plavix's final quarter04-26-12
Rumors put Bayer, Onyx at the M&A altar04-26-12
Watson formally unveils its $5.6B-plus deal for Actavis04-26-12
Under pressure, Brennan bows out as AstraZeneca CEO04-26-12
Hungry for new drugs, pharma pays big for biotech04-25-12
Novartis strikes back at production woes with new management04-25-12
Amgen joins Big Pharma's branded generics club with $700M deal04-25-12
Conflict threatens as FDA user-fee bills near a vote04-25-12
Spurned GSK chief: We're the 'compelling owner' for HGS04-25-12
GSK scrapes up 2% sales growth despite politics, generics04-25-12
Merck Serono to cut 580 Swiss jobs, close Geneva HQ04-24-12
Pradaxa hits blockbuster mark, swelling Boehringer sales 04-24-12
Diovan rivals, plant woes pinch Novartis profits04-24-12
Novartis wants U.K. to quash off-label Avastin use04-24-12
What will Amgen's new chief do with $20B cache?04-24-12
Watson set to unveil $5.9B Actavis buy, FT reports04-24-12
FDA prioritizes post-marketing drug safety, report says04-23-12
China sweeps up dozens in whirlwind drug-capsule probe04-23-12
Novartis blueprints $550M Swiss drug plant after layoffs backlash04-23-12
Pfizer gets $11.85B in nutrition sale to Nestlé04-23-12
Amylin's up for bid. Who'll step in line?04-23-12
FDA warns 56 more docs of fake Avastin supplies04-23-12
Reuters: Danone bids $11 billion for Pfizer baby formula business04-20-12
Merck KGaA plans to slash jobs in a socially responsible way04-20-12
Docs go off-label more than 10% of the time04-20-12
UPDATED: EMA approves Novartis' Gilenya04-20-12
Novo Nordisk, Public Citizen duke it out over Victoza04-20-12
China shuts down 10 drug capsulemakers04-20-12
HGS snubs $2.6B buyout offer from Benlysta partner GSK04-19-12
Pfizer, Amgen dissolving Enbrel partnership04-19-12
Roche acne drug linked to eye problems04-19-12
Judge accepts Merck unit's plea in Vioxx case04-19-12
Congressional bills would toughen safety labeling for generic drugmakers04-19-12
Baxter beats Wall Street projections but gets FDA questions on new treatment04-19-12
J&J plant fixes behind schedule, hampering brands' return04-18-12
Mylan pledges 500 new jobs in Irish expansion04-18-12
Roche decides to fold up its tent when Illumina offer expires04-18-12
Another day, another deal for Valeant's Pearson04-18-12
Humira sales leap helps power Abbott earnings04-18-12
The Future of Biopharma Manufacturing04-18-12
WSJ: Pfizer poised to sell nutrition biz to Nestlé for $9B-plus04-17-12
Forest profits reel as Lexapro faces first copycats04-17-12
J&J pharma revenues tick upward on new products, overseas sales04-17-12
How Amgen's CEO learned to listen--and why04-17-12
Glaxo CFO opens a new playbook04-17-12
Chinese regulators freeze sales of drugs with toxic capsules04-17-12
Supreme Court zeroes in on pharma reps' OT claims04-17-12
Pfizer's DTC ad spending dwarfs rivals 04-16-12
S. Africa ratchets up protection for domestic drugmakers04-16-12
Justice, J&J duel over Gorsky's contribution to kickback case04-16-12
With Zostavax supplies restored, Merck aims for revival04-16-12
French market toughens up on drug prices, safety04-16-12
GSK, sales rep lawyers argue OT case at Supreme Court04-16-12
UPDATED: Merck's Propecia and Proscar linked to sexual dysfunction04-12-12
Reuters: Money lined up for Watson to buy Actavis04-13-12
You can't cut your way to success, Lilly CEO declares04-13-12
Novartis reports patient taking Gilenya developed rare brain disease04-13-12
Icahn seeks records on why Amylin said no to Bristol-Myers04-13-12
Bloomberg: Bayer to pay $110 million to get out from under 500 Yaz lawsuits04-13-12
Merck's Propecia and Proscar linked to sexual dysfunction04-12-12
FDA to require prescriptions for farm antibiotics04-12-12
Sales-rep overtime steps into Supreme Court 04-12-12
J&J's $1.2B Risperdal fine 'ups the ante' for other cases04-12-12
Roche jeers at Illumina's boasts as proxy fight escalates04-12-12
Reuters: Watson aims for Actavis deal this month 04-12-12
Roche sales flat for Q1, but cancer meds shine04-12-12
Takeda snaps up URL Pharma in $800M+ deal04-11-12
UPDATED: Judge hits J&J with $1.1B penalty in Risperdal case04-11-12
FDA adds clotting data to Bayer's Yaz, Yasmin04-11-12
Humira takes top spot in drug sales04-11-12
Astellas, Lilly grab social-media limelight04-11-12
Vertex chief's pay dropped to $13.4M last year04-11-12
Jury verdict slaps J&J for Risperdal marketing 04-11-12
Should FDA change its rules to prevent another Tricor?04-10-12
Is M&A getting too pricey for smart drugmakers?04-10-12
Patients put a high value on cancer meds--and on hope04-10-12
Predictably, Icahn sues Amylin to open proxy fight04-10-12
J&J looks for workaround to ease Doxil shortage04-10-12
With Provigil exclusivity, Teva may hike its forecast04-10-12
UPDATED: Pfizer shrinking severance pay amid major cutbacks 04-06-12
Purdue plots $100M ad push for new sleep drug04-09-12
Victoza gets superior-to-Januvia data added to label04-09-12
AstraZeneca investors lobby for management shake-up04-09-12
Ranbaxy pulls ahead of Pfizer in Lipitor race04-09-12
After losing CEO race to Gorsky, J&J's McCoy jumps ship04-09-12
Novartis CEO explains how and why he cut jobs04-09-12
Pfizer shrinks worker severance packages04-06-12
Vaccines group in HPV price talks with Merck, GSK04-05-12
We'll be back on Monday, April 904-05-12
Watchdog says FDA should consider restricting Gilenya04-05-12
U.K. drug costs drop as blockbusters go off patent 04-05-12
CHMP chair makes sudden exit from EMA04-05-12
'Animal rule' allowed for J&J drug backed for new approval04-05-12
Lawmakers pressure CMS to get going on doc-disclosure rules04-05-12
Icahn pushes Amylin board to open up for sale04-04-12
IOM gives FDA to-do list for securing global drug supplies04-04-12
Politics, pharma sins sap wider use of Gardasil04-04-12
U.S. drug spending up, thanks to new drug launches04-04-12
Pfizer eyes ad agency work for cost-cutting04-04-12
More phony Avastin pops up in U.S.04-04-12
FDA battling White House over politicization of regulation04-03-12
S. Korean drugmakers sue to block price cuts04-03-12
Judge lets sex-bias suit against Bayer go ahead04-03-12
Forest pins new hopes on Bystolic with rights buyout04-03-12
Barred OTC drugmaker calls FDA oversight 'absurd'04-03-12
Eisai discount doesn't sway NICE on Halaven04-03-12
Traditional meds pose tough challenge to manufacturing04-03-12
GSK's Witty winning at pharma chess in post-blockbuster era04-02-12
Check out the new and improved FiercePharma.com04-02-12
An Etch-a-Sketch picture of J&J CEO-to-be Alex Gorsky04-02-12
Ranbaxy ships Indian-made Lipitor copies to U.S.04-02-12
Can pricey cancer drugs outlast austerity?04-02-12
Lawsuits against Pfizer's Celebrex, Bextra get class action status03-30-12
UPDATED: Dendreon's Provenge faces new questions03-30-12
AstraZeneca's Seroquel XR patent upheld in U.S. 03-30-12
France's drug spending will shrink for first time, IMS says03-30-12
Bayer gets positive ruling from NICE on Xarelto03-30-12
Rare-disease drugs won't help out-of-work pharma reps04-02-12
Check out the new and improved FiercePharma layout03-30-12
North Carolina considers drug liability protections03-30-12
Hikma to plow $300M into M&A, internal growth04-02-12
Astellas extends Lipitor marketing deal with Pfizer03-29-12
Judge denies AZ's bid to stop Seroquel copies, but chides FDA03-29-12
Drugs made by Sun Pharma, Cipla recalled in U.S.03-29-12
Sanofi launches iPhone glucose monitor, diabetes coaching03-29-12
Allergan asks FDA for lucrative new Botox indication03-29-12
Who's next to move on Amylin? Analysts say Big Pharma looms03-29-12
Vytorin outcomes study barrels on without a peek03-28-12
Bloomberg: Watson on verge of deal for Actavis03-28-12
Amylin reportedly stiff-armed $3.5B offer from BMS03-28-12
Affymax approval breaks Amgen's long anemia monopoly03-28-12
Judge slams FDA for importing lethal-injection drugs03-28-12
Pfizer open to Abbott-style split, analyst says03-28-12
Arkansas jury hears state's claims against J&J03-27-12
Dr. Reddy's nears launch of Fujifilm venture, CFO says03-27-12
ISTA's hard-to-get stance yields $500M Bausch & Lomb bid03-27-12
U.S. questions India's IP regime after Nexavar move03-27-12
Biogen chief brings in $11.3M in 2011 pay03-27-12
Judge: FDA must follow up on farm antibiotics ban03-27-12
With patent running out, AZ loses bid to block Seroquel copies03-26-12
Valeant nabs Russia's Natur Produkt for $175M-plus03-26-12
AZ's Brennan nabs 11% pay hike to $5.89M03-26-12
Roche to offer cancer drugs in India at deep discounts03-26-12
Bare shelves in docs' sample closets as pharma overhauls sales03-26-12
J&J's Risperdal cases head to court in Texas, Arkansas03-26-12
UPDATED: EMA OKs Byetta for expanded treatment03-23-12
Cheap generic stops bleeding effectively but gets little use03-23-12
Merck to invest in Canadian VC fund03-23-12
GlaxoSmithKline undeterred by spotty results for Relovair03-23-12
EMA OKs Byetta for expanded treatment03-23-12
British Medical Journal focuses on questionable patent extension03-23-12
FDA seeks advice on making more drugs OTC03-23-12
Meet the new publisher of FiercePharma03-23-12
Merck Canada putting $100 million into VC firm03-23-12
Study: No reason teens can't buy emergency contraception OTC03-22-12
Is AZ aiming for a Forest buy?03-22-12
Health Canada tells hospitals to quarantine morphine from Sandoz03-22-12
GSK to build new U.K. site, create up to 1,000 jobs03-22-12
Paper: Merck KGaA won't resort to massive layoffs to trim German workforce03-22-12
Is Watson poised to grab Actavis?03-22-12
Pharma sales execs: Current model is broken; changes are coming03-21-12
Teva to jump to NYSE03-21-12
Targacept management acknowledges layoffs are possible03-21-12
Pfizer to pay $3.3M to settle Zyvox probe03-21-12
FDA panel backs GSK's Votrient for soft-tissue sarcoma 03-21-12
Sandoz: We won't hike prices in Canada during shortage03-21-12
Bayer, others fined $15.9M by Romanian competition authority03-20-12
Indian government defends country's generics industry 03-20-12
Lilly to focus on diabetes, cancer in China03-20-12
UPDATED: Apotex recalls BP med over empty capsules03-20-12
Groups urge FTC to investigate vaccine 'bundling'03-20-12
Eisai eyes job creation in U.K. with facility ops expansion03-20-12
GSK to eavesdrop on social-media chatter with IT deal03-19-12
Treatment gap: Women get fewer standard heart drugs03-19-12
Ex-Roche rep wins $1.8M in age discrimination suit03-19-12
M&A in Turkey, Indonesia underscore emerging-markets lure03-19-12
Roche exec expects 'limited' rebound for pharma03-19-12
Abbott execs take pay cuts, but White still nabs $24M03-19-12
Bayer makes prelim offer for Pfizer's animal health unit03-16-12
Mylan bows out of Rottapharm bidding03-16-12
Hamburg says FDA needs more leeway to combat drug fakes03-16-12
Can European pharma's cash flow cover buyback plans?03-16-12
Setting new course, Pfizer CEO gets 44% pay hike 03-16-12
Novartis persuades NICE to endorse Gilenya03-16-12
Divestments 'not a trivial exercise,' Read tells FT03-15-12
As Shire gives up on Replagal in U.S., Sanofi stands to gain03-15-12
Stada stymied in bids for Russian M&A03-15-12
Forest mourns as Teva celebrates launch of generic Lexapro03-15-12
GSK offloads consumer brands to Omega, delays Alli sale03-15-12
J&J's Weldon due for $143M retirement package03-15-12
Chinese officials intent on 'Anhui model' for price cuts03-14-12
UPDATED:Pfizer's marketing pact with Biocon falls apart03-13-12
Austrian racks up millions from parallel trade in EU03-14-12
Judge chooses lead lawyers in Actos litigation03-14-12
Bayer eyes 16% pharma growth on new meds03-14-12
Novo seen to benefit from Pfizer-Biocon split03-14-12
Sanofi to shutter Plavix-producing U.K. plant03-14-12
After big hike in 2011, GSK CEO's pay set to jump again03-13-12
Allergan wins injunction against Botox rival03-13-12
Pfizer's marketing pact with Biocon falls apart03-13-12
Japan may open door to more foreign-approved drugs03-13-12
AstraZeneca sues FDA to block Seroquel copies03-13-12
Feds reportedly demand $1.8B in Risperdal marketing probe03-13-12
Fake Avastin case highlights need for supply-chain controls03-12-12
Pfizer aims to jump start stalled arthritis-pain drugs03-12-12
FDA drafts rules for prior review of DTC television ads03-12-12
Indian government forces Bayer to accept generic Nexavar competition03-12-12
U.S. wants more than $1B from J&J in Risperdal settlement03-12-12
Widow's lawsuit claims Fabrazyme shortage led to husband's death03-12-12
AMSA endorses more med school conflicts policies03-09-12
With Seroquel petition denied, AZ needs M&A03-09-12
Biopharma workers balance good, bad and ugly in new survey03-09-12
New Zytiga use could double sales potential03-09-12
Bayer Healthcare posts big growth in Asia Pacific03-09-12
Generics deals drive increase in pharma M&A03-09-12
Zytiga data presents new threat to Provenge03-08-12
Bayer, Novartis circle Pfizer's animal health unit03-08-12
GSK takes bids in European consumer-drug sale03-08-12
FDA may let pharma sell more drugs without scripts03-08-12
AIDS advocates spar over preventive Truvada use03-08-12
Health plans sue Big Pharma over co-pay coupons03-08-12
AARP finds nearly 26% increase in retail drug prices03-07-12
Viehbacher up on Boston, emerging markets, down on corporate innovation03-07-12
Gilenya market share drops after FDA review03-07-12
Fake Avastin adds urgency to foreign-drug importation probe03-07-12
Pradaxa patient's death draws more scrutiny of bleeding risks03-07-12
Whistleblower claims Takeda blunted Actos heart reports03-07-12
AZ mulls buy-or-sell options for Indian unit03-06-12
Roche can shop around if Illumina bid fails, Humer says03-06-12
Shire pits Vyvanse against Concerta in ADHD trials03-06-12
Copycat Lipitor hits in 4 EU countries03-06-12
HHS: Misbehaving drugmakers could lose patent rights03-06-12
More reps sue Novo for back overtime03-06-12
Chinese official chides hospitals for high drug prices03-05-12
Merck's new cholesterol combo faces delay03-05-12
How worrisome is the statin-diabetes link?03-05-12
Greece making drugmakers cover overspending on meds03-05-12
GSK to add hundreds to Chinese sales force, CEO says03-05-12
EC drops antitrust probe aimed at GSK03-05-12
How much cheaper will biosimilars be? 03-02-12
European regulators take steps to speed pricing, reimbursement decisions03-02-12
Is Teva considering a jump to NYSE?03-02-12
Sources: Nestle leads in Pfizer unit bid, but don't count out Danone-Mead03-02-12
Indian regulators, alleging overpricing, demand $86M from Cipla03-02-12
Columbia Labs to cut 42% of workforce after FDA snub03-02-12
Chinese pharmas feel the squeeze of healthcare reform03-02-12
Pharma group adopts stringent conduct code03-01-12
GSK, Daiichi team to develop, launch vaccines in Japan03-01-12
Greece adopts more drug budget cuts03-01-12
Elan chief to stick around until Alzheimer's data breaks03-01-12
Pradaxa, Xarelto gain reprieve as FDA delays Eliquis decision03-01-12
EC antitrust squad drops AZ-Nycomed probe03-01-12
FDA scolds Merck for missing Januvia deadline 02-29-12
FDA flags diabetes risks with statin drugs02-29-12
Serbian bribery probe highlights emerging-markets danger02-29-12
FDA cites contaminated vials, insects in APP warning letter02-29-12
Mylan aims first Lexapro copy at Forest Labs02-29-12
Analysts eye Big Pharma suitors for Vivus02-29-12
Bayer cuts debt for freedom to make 'significant' acquisition02-28-12
Pfizer puts Emergen-C into its consumer med cabinet02-28-12
Bribery rampant in Vietnamese drug market, study finds02-28-12
In drugs vs. stents debate, another point for meds02-28-12
Phony Avastin vials contained chemicals, but no drugs02-28-12
FDA puts Xarelto's ACS indication on fast track02-28-12
Lilly adds to Irish ops with $440M plant02-27-12
Surveyed docs see need for new prostate-cancer meds, Medivation says02-27-12
J&J chief gets stepped-up bonus for 201102-27-12
Cost and job cuts coming soon to Merck KGaA 02-27-12
GSK chief: Officials delay new meds to save money02-27-12
GSK pulls drug made at troubled Novartis plant02-27-12
Mortality risks vary with antipsychotics in dementia patients02-24-12
GSK hits back at XenoPort in RLS drug dispute02-24-12
Novartis meningitis vax faces tough fight02-24-12
Field narrows in contest for Pfizer's nutrition unit02-24-12
U.K. enjoys bargain-basement drug prices, report finds02-24-12
Bogus Avastin has cropped up repeatedly, WSJ finds 02-24-12
Actelion inks $70M deal for Auxilium's Xiaflex02-23-12
Now, Vivus has to gear up for probable Qnexa launch02-23-12
$500M charge eats away at Ranbaxy's Q4 sales hike02-23-12
CDC delay could temper adult uptake of Pfizer's Prevnar shot02-23-12
FDA adds 14 Chinese suppliers to heparin hot list02-23-12
Teva wraps up most propofol suits for $285M02-22-12
Biotech investors collect a fraction of milestone cash02-22-12
J&J picks Gorsky over McCoy to fill CEO's seat02-22-12
Mexico's Genomma lodges $834M bid for Prestige02-22-12
Shire to boost Vpriv, Replagal with EMA-approved plant02-22-12
Abbott prevails as Supremes pass on J&J patent suit02-22-12
Fake Avastin's path shows tangled global supply chain02-21-12
Should doc-payment rules require more info?02-21-12
Pfizer reportedly weighing animal health IPO02-21-12
FDA brings Sun's Doxil copy online to fix shortage02-21-12
With Hisun JV inked, Pfizer eyes other Chinese tie-ups02-21-12
Quebec plant fixes force Sandoz to slash output02-21-12
Novartis to revamp Rasilez label with safety risks02-17-12
Jury says J&J's Risperdal didn't cause plaintiff's diabetes02-17-12
FiercePharma learns there's no such thing as Presidents Day02-17-12
NICE asks for more info on first-line Tarceva use02-17-12
Finding study flaws, EMA backpedals on Trasylol suspension02-17-12
J&J pulls infant Tylenol on dosing-system issue02-17-12
AZ sells discounted cancer drug directly to patients02-17-12
Leukemia drug shortage averted for now, FDA says02-16-12
Wyeth puts $960M squeeze on Sun for Protonix launch02-16-12
Sanofi yanks drug batch on CMO contamination fears02-16-12
NICE holds out for more data on Botox for migraine02-16-12
Fake Avastin may not be the only counterfeit on doctors' shelves02-16-12
A bright side to Europe's woes: U.S., Japan look better02-15-12
Teva scrambling toward post-Copaxone future02-15-12
Idled Hospira plant now back online with new management02-15-12
GSK wraps up another 25,000 Avandia suits02-15-12
FDA, Roche probe bogus Avastin found in U.S.02-15-12
Merck gains traction in Brazil with joint venture02-15-12
Old drug + potential new use = headache for pharma02-14-12
Pharma remains heartburn HQ as 44% fear job loss02-14-12
GSK's office-space overhaul part of bigger changes02-14-12
Obama budget digs deep into pharma's wallet02-14-12
Greek pharma cuts amount to $1.3B02-14-12
Hospira's quality issues weigh on Q4 results, 2012 forecast02-14-12
Gene study finds tumor-cell flaw possibly vulnerable to Pfizer, AZ cancer meds 02-13-12
Lonza teams with S. Africa on antiretroviral API plant02-13-12
Novartis dealt another setback to broader Menveo use02-13-12
After dropping ISTA, Valeant nabs another eye-drug company02-13-12
German data provider accused of selling private script info02-13-12
Ben Venue's idled plant triggers 'dire' leukemia-drug shortage02-13-12
WellPoint to drop branded Lipitor from its formulary02-10-12
Psychologists petition against DSM-5 revisions02-10-12
GSK, Takeda say nay to in-house diagnostics units02-10-12
Condemned prisoners challenge execution-drug imports02-10-12
Merck says Victrelis can interfere with HIV meds 02-10-12
LEO Pharma slapped with sales-rep overtime suit02-10-12
Novartis CEO calls external focus key to fast-changing pharma02-09-12
FDA panel nixes new use for Amgen's Xgeva02-09-12
Watson chief has big brand plans for $6B war chest02-09-12
Shire upbeat on 2012 as earnings top estimates02-09-12
Judge: No 1st Amendment shield for Astellas' Prograf petition02-09-12
Eisai renews focus on 'more attractive' Japan02-08-12
Don't look for Lundbeck earnings growth until 201502-08-12
FDA issues safety alert about PPIs and C. diff 02-08-12
Sanofi, BMS collect their $444M in Plavix damages02-08-12
GSK moves European cash to U.K. nightly 'just in case'02-08-12
Sanofi CEO: Look out below, profits are falling02-08-12
Hang on just a bit longer for sales growth, GSK chief says02-07-12
Daiichi shops India for bolt-on deals, ET says02-07-12
How do the 12 priciest drugs in the U.S. stack up?02-07-12
Reuters: Nestle leads pack of bidders for Pfizer nutrition unit02-07-12
Bayer CEO: Shortsighted price cuts lead to long-term pain02-07-12
What can Big Pharma learn from an NYT bestseller?02-07-12
Lilly hunkers down for lean years with salary freeze02-06-12
Drugmakers aim to dampen risks in slow-paying countries02-06-12
Is Sanofi destined to be 'small player' in MS?02-06-12
Medicaid proposal would let states figure base prices02-06-12
NICE eyes NHS formularies for excluded drugs02-06-12
Amgen's Xgeva faces doubters on new indication02-06-12
Botox delivers for Allergan, Dr. Reddy's sees big profit increase during quarter02-03-12
Astellas scores highest in Japanese M&A bout02-03-12
FDA talks, but doctors don't necessarily listen02-03-12
Gloom for the pharma industry, yes. Doom? No02-03-12
Mediator probe rolls on with searches at Afssaps, executives' homes02-03-12
As blockbuster drugs fade, so does TV advertising02-03-12
Novartis investor group urges vote against Vasella's pay02-02-12
Novo amps up 2012 expectations on strong Victoza sales02-02-12
Merck's diabetes drugs offset Remicade sales decline02-02-12
GSK resolves 20K more Avandia lawsuits, lawyer says02-02-12
NICE rejects J&J's Zytiga as too expensive02-02-12
AstraZeneca puts 7,300 jobs on the chopping block 02-02-12
What will Dendreon's new chief do about Provenge?02-01-12
Roche results spotlight targeted-drug strategy02-01-12
Pfizer pulls mixed-up contraceptive pills02-01-12
Vertex backs up pricey new CF drug with co-pay help02-01-12
FDA's new-drug approvals of 201102-01-12
FDA finds puppies and moths not guilty of DTC interference02-01-12
Depressed study subjects spell relief with Special K01-31-12
Spain's drug spending drops as pharma debt mounts01-31-12

SourceSolution © 2008-2012